GET DAILY SIGNALSDocGo (DCGO) Shares Drop -30% in 30 Days as Revenue Transition Weighs on Sentiment
Key Takeaways
- DocGo shares declined roughly 30% over the trailing 30 days, sliding from about $0.37 in early October to approximately $0.26, after touching a 52-week low near $0.21.
- The pullback extends a longer downtrend: the stock has fallen about 60% over the past three months.
- Persistent pressure reflects the wind-down of migrant-related revenue, ongoing adjusted EBITDA losses, and investor caution around the pending Hicuity Health acquisition.
- Core operating lines — SteadyMD virtual care, medical transportation, and mobile phlebotomy — continue to grow, with management targeting positive EBITDA exiting 2026.
- Third-quarter 2026 results are scheduled for release on November 9, 2026, making it a pivotal near-term catalyst for the stock.
- For more detail, review the company's Price Targets, Earnings, and Forecast pages to track valuation, fundamentals, and forward-looking expectations.
- Investors seeking additional signals can explore Trending AI Robots for automated trading ideas and performance analytics.
DocGo (DCGO) Business Overview
DocGo Inc. is a technology-enabled mobile health and medical transportation services company operating in the United States and the United Kingdom. Through its integrated platform, the company delivers care outside traditional facilities, combining mobile health services, remote patient monitoring, ambulance and non-emergency medical transportation under its Ambulnz brand, and a 50-state virtual care network. Its SteadyMD virtual care offering supports telehealth, weight-management, and general clinical services, while its mobile phlebotomy and care-gap-closure programs serve payers, hospital networks, and municipalities.
The company positions itself as a proactive healthcare provider that bridges physical and virtual care by dispatching certified field staff to patients at home or work. Investors follow the stock for its growth across virtual and in-home care, its expansion into new markets such as the United Kingdom, and its efforts to return to profitability following a period of restructuring tied to the wind-down of migrant-related projects. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Price Action: -30% Over 30 Days and -60% Over Three Months
Over the trailing 30 days, DCGO fell roughly 30%, moving from a close near $0.37 in early October to about $0.26 at the latest reading. The decline was not linear: shares slid through mid-October before stabilizing in a lower range near $0.25–$0.27, then dropped again in early November to a 52-week low of approximately $0.21.
The broader three-month picture is steeper still. From around $0.65 at the start of August, the stock has lost roughly 60% of its value. The sharpest single leg lower occurred in mid-August, when shares fell from above $0.70 to below $0.48, coinciding with the company's second-quarter earnings report and updated guidance. The subsequent two months have been defined by persistent downward momentum rather than a single headline event.
Factors Behind the 30-Day Decline
The 30-day decline reflects a continuation of negative sentiment rather than one isolated catalyst. Several verified factors contributed to the pressure:
- Revenue headwinds: The company's reported revenue declines have been driven entirely by the wind-down of migrant-related projects, a process that has clouded headline growth even as non-migrant lines expand.
- Profitability concerns: DocGo has continued to post adjusted EBITDA losses, and management's guidance points to a full-year 2026 adjusted EBITDA loss, weighing on investor confidence.
- Acquisition uncertainty: The pending acquisition of Hicuity Health, a provider of tele-ICU, virtual nursing, and telemetry monitoring services, has introduced integration and financing questions that have contributed to caution.
- Small-cap and sector pressure: Digital-health and small-cap healthcare names have faced broader selling, and DCGO's slide below prior support levels into a 52-week low compounded the move.
The stock's approach of its November 9 third-quarter earnings release also kept risk-sensitive investors on the sidelines, with the shares trading at sharply reduced levels into the print.
Drivers of the Three-Month Downtrend
The three-month downtrend is rooted in the company's transition away from migrant-related services. While this wind-down pressured revenue, management has emphasized underlying momentum in higher-value lines: SteadyMD generated more than $9 million in first-quarter revenue, mobile phlebotomy is projected to grow as much as 75% in 2026, and medical transportation posted record quarterly revenue. In the second quarter, total revenue of $73.4 million declined year over year solely on the migrant wind-down, while full-year guidance was narrowed to the $305 million–$310 million range.
Despite these operating strides, the market has focused on the path to profitability. Management has targeted a positive EBITDA run rate exiting 2026, but until that milestone is demonstrated, the stock has remained under pressure. The mid-August earnings-driven selloff established a lower trading range that has persisted into early November. From what I see, reviewing forward estimates on Tickeron’s AI Trend Prediction Engine helps put these trends in context.
Near-Term Catalysts and What to Watch
Investors should monitor several factors in the near term. The November 9, 2026 third-quarter earnings report and management's updated commentary on full-year guidance will be the primary catalyst, particularly any progress toward the company's EBITDA-breakeven target. The completion and integration of the Hicuity Health acquisition — including associated cost synergies and cross-selling opportunities — will also shape sentiment.
Beyond company-specific news, regulatory developments warrant attention: management has flagged a proposed CMS rule that could affect Medicare reimbursement for remote patient monitoring, a dynamic that could influence the virtual care landscape. Continued execution in SteadyMD, mobile phlebotomy expansion, and medical transportation contract renewals will be important gauges of underlying demand. Finally, macroeconomic conditions affecting small-cap equities and healthcare-sector financing will continue to influence trading in the stock. These observations are informational and do not constitute investment advice or a prediction of future performance.
Using AI Tools in My Research Process
In my own analysis, I frequently turn to Tickeron’s suite of AI-powered tools to supplement fundamental research and identify patterns across the market. The AI Trading Bots platform, for instance, provides access to hundreds of automated strategies that monitor thousands of tickers, allowing me to evaluate performance metrics and timeframes that align with current conditions. This approach helps surface data-driven ideas without replacing my own due diligence on names like DCGO.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for DCGO turns negative, indicating new downward trend
DCGO saw its Momentum Indicator move below the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned negative. In 82 of the 90 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for DCGO turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 42 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DCGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DCGO entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +5.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where DCGO advanced for three days, in 186 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
DCGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.178) is normal, around the industry mean (204.027). P/E Ratio (-0.110) is within average values for comparable stocks, (19.383). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.092) among similar stocks. P/S Ratio (0.127) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. DCGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DCGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement